Cardiac Safety London

Event Date:
Wednesday 20th May 2020 - 10am – 3.30pm BST
Location:
Online Event
View ProgramView Program

To help to enrich and speed up your drug development programs, join us for a day of discovery as global experts in Cardiology, Pharmacology and Diabetes discuss the latest state of the art methods in early phase clinical research. The event will provide insight to enable better patient outcomes, efficiency, and cost-effectiveness in global drug development.

The 20th of May also is World Clinical Trials Day celebrating the anniversary of the first clinical trial by James Lind in 1747 into the causes of scurvy on board the HMS Salisbury. On this occasion, we will also showcase work from our Research Institute, our not-for-profit affiliate dedicated to academic research.


Programme

  • Updates on the CSRC white paper on cardiac safety assessments of anti-diabetic medicines
  • Waveform analysis and measurements of QT subintervals
  • Repolarization disturbances in type 1 long QT syndrome patients
  • Cardiac safety embedded in adaptive clinical trials
  • Sex differences in cardiac risk
  • Regulatory updates in drug development
  • Preclinical science and models in cardiac safety assessments
  • Modelling and statistics of pharmacodynamic markers

Click here to view the agenda

This is an online event, to express an interest in this event or to learn more details please contact Jack Wilmott on j.wilmott@richmondpharmacology.com

Latest news

Upcoming Event

EUFEMED, 3rd Annual Conference, 28-30 April 2021

28-30 April 2021
Dr Jorg Taubel will co-chair a session on day one, which explores how technology has reduced the risks of pandemic effects on Phase I and II trial performance.
View event

Richmond Pharmacology listed in the Alantra Pharma Fast 50

July 13, 2021
Richmond has been included in a top 50 list of the UK’s fastest-growing, privately-owned pharmaceutical businesses. 
Read more

Richmond Pharmacology listed in the J.P. Morgan Top 200 Female Powered Businesses

June 29, 2021
J.P. Morgan has identified Richmond Pharmacology as a high-growth female-powered business in its annual 'Top 200 Female Powered Businesses' list 2021.
Read more

CRISPR-Cas9 in-vivo gene editing shows reduction in TTR after a single dose

June 29, 2021
Data produced through Intellia Therapeutic’s NTLA-2001 FIH clinical trial, conducted at Richmond Pharmacology, indicates a reduction in the faulty TTR protein after a single infusion. Results were presented by Professor Julian Gillmore at this year’s Peripheral Nerve Society Annual Meeting.
Read more